<p>阿布图斯生物制药公司（NASDAQ:ABUS - 获取免费报告）在周四的交易中，其股价突破了 200 日移动平均线。该股票的 200 日移动平均线为 3.56 美元，最高交易价为 4.65 美元。阿布图斯生物制药的股票最后交易价为 4.51 美元，成交量为 1,636,435 股。</p>
<p>获取 <strong>阿布图斯生物制药</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>3 只股票适合购买以应对 COVID 复苏</li>
</ul>
<p>几位分析师最近对 ABUS 股票发布了报告。Weiss Ratings 在 10 月 8 日的报告中重申了对阿布图斯生物制药股票的 “卖出（d-）” 评级。华尔街 Zen 在 9 月 5 日的报告中将阿布图斯生物制药的股票评级从 “买入” 下调至 “持有”。最后，Chardan Capital 在 8 月 11 日的研究报告中重申了 “买入” 评级，并对阿布图斯生物制药的股票设定了 5.00 美元的目标价。三位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 5.00 美元。</p>
<p><strong>查看我们最新的阿布图斯生物制药股票报告</strong></p>
<h2>阿布图斯生物制药价格表现</h2>
<p>该股票的市值为 8.6457 亿美元，市盈率为-15.55，贝塔值为 1.09。该股票的 50 日简单移动平均线为 4.07 美元，200 日简单移动平均线为 3.56 美元。</p>
<p>阿布图斯生物制药（NASDAQ:ABUS - 获取免费报告）最近在 8 月 6 日公布了季度财报。这家生物制药公司报告的每股收益（EPS）为 0.01 美元，超出分析师共识预期的-0.02 美元，超出幅度为 0.03 美元。该公司在本季度的收入为 1074 万美元，而分析师的预期为 221 万美元。阿布图斯生物制药的净利润率为-352.24%，股本回报率为-59.28%。整体来看，分析师预测阿布图斯生物制药公司在本年度将发布-0.39 的每股收益。</p>
<h2>机构投资者对阿布图斯生物制药的看法</h2>
<p>机构投资者最近增加或减少了对该股票的持仓。Oxford Asset Management LLP 在第二季度新购入了阿布图斯生物制药的股份，价值约 38,000 美元。大和证券集团在第二季度将其在阿布图斯生物制药的持仓增加了 3911.1%。大和证券集团目前拥有 15,844 股该生物制药公司的股票，价值 49,000 美元，此前在该期间内又购入了 15,449 股。保诚金融公司在第二季度将其在阿布图斯生物制药的持仓增加了 71.5%。保诚金融公司目前拥有 18,255 股该生物制药公司的股票，价值 56,000 美元，此前在上个季度又购入了 7,610 股。洛杉矶资本管理公司在第二季度新购入了阿布图斯生物制药的股份，价值 61,000 美元。最后，Tower Research Capital LLC TRC 在第二季度将其在阿布图斯生物制药的持仓增加了 220.1%。Tower Research Capital LLC TRC 目前拥有 20,760 股该生物制药公司的股票，价值 64,000 美元，此前在该期间内又购入了 14,275 股。43.79% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于阿布图斯生物制药</h2>
<p>（获取免费报告）</p>
<p>阿布图斯生物制药公司是一家生物制药公司，专注于开发针对美国慢性乙型肝炎病毒（HBV）感染的新型治疗药物。其 HBV 产品管线包括 imdusiran（AB-729），这是一种专有的皮下给药 RNAi 治疗产品候选药物，能够抑制所有 HBV 抗原的表达，包括 HBsAg。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过阿布图斯生物制药</li>
<li>最佳航空航天股票投资</li>
<li>Salesforce 期待已久的转折点来了：继续上涨！</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>Rocket Lab USA 获得华尔街的认可：是时候购买了吗？</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>Archer 收购竞争对手的专利宝藏，进行战略性举措</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在阿布图斯生物制药吗？</h2>
<p>在考虑阿布图斯生物制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而阿布图斯生物制药并不在名单上。</p>
<p>虽然阿布图斯生物制药目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ABUS

<p>Arbutus Biopharma 的股票（NASDAQ:ABUS）已超过其 200 日移动平均线，交易价格为 4.51 美元，成交量为 1,636,435 股。分析师的评级意见不一：Weiss Ratings 维持 “卖出” 评级，而 Chardan Capital 则给予 “买入” 评级，目标价格为 5.00 美元。该公司报告的季度每股收益为 0.01 美元，超出预期，收入为 1074 万美元。机构投资者持有 43.79% 的股份，显示出显著的兴趣。该股票的市值为 8.6457 亿美元，净利润率为负 352.24%</p>

<p>Arbutus Biopharma Corporation (NASDAQ:ABUS - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.56 and traded as high as $4.65. Arbutus Biopharma shares last traded at $4.51, with a volume of 1,636,435 shares trading hands.</p>
<div class="lb-trans"><p>阿布图斯生物制药公司（NASDAQ:ABUS - 获取免费报告）在周四的交易中，其股价突破了 200 日移动平均线。该股票的 200 日移动平均线为 3.56 美元，最高交易价为 4.65 美元。阿布图斯生物制药的股票最后交易价为 4.51 美元，成交量为 1,636,435 股。</p>
</div><p>Get <strong>Arbutus Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>阿布图斯生物制药</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>3 Stocks to Buy For the COVID Resurgence</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只股票适合购买以应对 COVID 复苏</li>
</ul>
</div><p>Several analysts recently issued reports on ABUS shares. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Arbutus Biopharma in a report on Wednesday, October 8th. Wall Street Zen cut shares of Arbutus Biopharma from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, September 5th. Finally, Chardan Capital reaffirmed a &#34;buy&#34; rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $5.00.</p>
<div class="lb-trans"><p>几位分析师最近对 ABUS 股票发布了报告。Weiss Ratings 在 10 月 8 日的报告中重申了对阿布图斯生物制药股票的 “卖出（d-）” 评级。华尔街 Zen 在 9 月 5 日的报告中将阿布图斯生物制药的股票评级从 “买入” 下调至 “持有”。最后，Chardan Capital 在 8 月 11 日的研究报告中重申了 “买入” 评级，并对阿布图斯生物制药的股票设定了 5.00 美元的目标价。三位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 5.00 美元。</p>
</div><p><strong>View Our Latest Stock Report on Arbutus Biopharma</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的阿布图斯生物制药股票报告</strong></p>
</div><h2>Arbutus Biopharma Price Performance</h2>
<div class="lb-trans"><h2>阿布图斯生物制药价格表现</h2>
</div><p>The stock has a market cap of $864.57 million, a price-to-earnings ratio of -15.55 and a beta of 1.09. The stock's 50 day simple moving average is $4.07 and its two-hundred day simple moving average is $3.56.</p>
<div class="lb-trans"><p>该股票的市值为 8.6457 亿美元，市盈率为-15.55，贝塔值为 1.09。该股票的 50 日简单移动平均线为 4.07 美元，200 日简单移动平均线为 3.56 美元。</p>
</div><p>Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.03. The company had revenue of $10.74 million during the quarter, compared to analysts' expectations of $2.21 million. Arbutus Biopharma had a negative net margin of 352.24% and a negative return on equity of 59.28%. As a group, analysts predict that Arbutus Biopharma Corporation will post -0.39 earnings per share for the current year.</p>
<div class="lb-trans"><p>阿布图斯生物制药（NASDAQ:ABUS - 获取免费报告）最近在 8 月 6 日公布了季度财报。这家生物制药公司报告的每股收益（EPS）为 0.01 美元，超出分析师共识预期的-0.02 美元，超出幅度为 0.03 美元。该公司在本季度的收入为 1074 万美元，而分析师的预期为 221 万美元。阿布图斯生物制药的净利润率为-352.24%，股本回报率为-59.28%。整体来看，分析师预测阿布图斯生物制药公司在本年度将发布-0.39 的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Arbutus Biopharma</h2>
<div class="lb-trans"><h2>机构投资者对阿布图斯生物制药的看法</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the stock. Oxford Asset Management LLP acquired a new position in shares of Arbutus Biopharma in the 2nd quarter worth approximately $38,000. Daiwa Securities Group Inc. grew its position in Arbutus Biopharma by 3,911.1% in the second quarter. Daiwa Securities Group Inc. now owns 15,844 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 15,449 shares during the period. Prudential Financial Inc. raised its stake in Arbutus Biopharma by 71.5% during the second quarter. Prudential Financial Inc. now owns 18,255 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 7,610 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Arbutus Biopharma during the second quarter valued at $61,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Arbutus Biopharma by 220.1% during the second quarter. Tower Research Capital LLC TRC now owns 20,760 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 14,275 shares during the period. 43.79% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近增加或减少了对该股票的持仓。Oxford Asset Management LLP 在第二季度新购入了阿布图斯生物制药的股份，价值约 38,000 美元。大和证券集团在第二季度将其在阿布图斯生物制药的持仓增加了 3911.1%。大和证券集团目前拥有 15,844 股该生物制药公司的股票，价值 49,000 美元，此前在该期间内又购入了 15,449 股。保诚金融公司在第二季度将其在阿布图斯生物制药的持仓增加了 71.5%。保诚金融公司目前拥有 18,255 股该生物制药公司的股票，价值 56,000 美元，此前在上个季度又购入了 7,610 股。洛杉矶资本管理公司在第二季度新购入了阿布图斯生物制药的股份，价值 61,000 美元。最后，Tower Research Capital LLC TRC 在第二季度将其在阿布图斯生物制药的持仓增加了 220.1%。Tower Research Capital LLC TRC 目前拥有 20,760 股该生物制药公司的股票，价值 64,000 美元，此前在该期间内又购入了 14,275 股。43.79% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Arbutus Biopharma</h2>
<div class="lb-trans"><h2>关于阿布图斯生物制药</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.</p>
<div class="lb-trans"><p>阿布图斯生物制药公司是一家生物制药公司，专注于开发针对美国慢性乙型肝炎病毒（HBV）感染的新型治疗药物。其 HBV 产品管线包括 imdusiran（AB-729），这是一种专有的皮下给药 RNAi 治疗产品候选药物，能够抑制所有 HBV 抗原的表达，包括 HBsAg。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Arbutus Biopharma</li>
<li>Best Aerospace Stocks Investing</li>
<li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过阿布图斯生物制药</li>
<li>最佳航空航天股票投资</li>
<li>Salesforce 期待已久的转折点来了：继续上涨！</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>Rocket Lab USA 获得华尔街的认可：是时候购买了吗？</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>Archer 收购竞争对手的专利宝藏，进行战略性举措</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arbutus Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在阿布图斯生物制药吗？</h2>
</div><p>Before you consider Arbutus Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿布图斯生物制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arbutus Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而阿布图斯生物制药并不在名单上。</p>
</div><p>While Arbutus Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿布图斯生物制药目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Arbutus Biopharma（NASDAQ:ABUS）的股价已超过 200 日移动平均线 - 现在是卖出的时候吗？